{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+Mutant+Solid+Tumors&page=2", "query": { "condition": "KRAS Mutant Solid Tumors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=KRAS+Mutant+Solid+Tumors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-25T18:03:49.105Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05462717", "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Pancreatic Ductal Adenocarcinoma", "Advanced Solid Tumor" ], "interventions": [ { "name": "RMC-6291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 222, "start_date": "2022-09-19", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 15, "location_summary": "Springdale, Arkansas • Orange, California • Sacramento, California + 10 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05462717" }, { "nct_id": "NCT06208124", "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor (Phase 1)", "Pancreas Adenocarcinoma", "Non-small Cell Lung Cancer", "Malignant Melanoma (Cutaneous)" ], "interventions": [ { "name": "IMM-6-415", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immuneering Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-02-27", "completion_date": "2025-04-30", "has_results": false, "last_update_posted_date": "2025-05-28", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Duarte, California • Denver, Colorado + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06208124" }, { "nct_id": "NCT06128551", "title": "Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (NSCLC)", "Colorectal Cancer", "Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Elironrasib", "type": "DRUG" }, { "name": "Daraxonrasib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 534, "start_date": "2023-11-14", "completion_date": "2029-06", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 21, "location_summary": "Duarte, California • Orange, California • Sacramento, California + 15 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06128551" }, { "nct_id": "NCT01986166", "title": "A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Cobimetinib", "type": "DRUG" }, { "name": "MEHD7945A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2013-11", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-07-18", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 6, "location_summary": "San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01986166" }, { "nct_id": "NCT03114319", "title": "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC)", "KRAS G12-mutant NSCLC", "Esophageal Squamous Cell Cancer (SCC)", "Head/Neck SCC", "Melanoma", "Advanced Gastrointestinal Stromal Tumors (GIST)", "Advanced NRAS/BRAFT wt Cutaneous Melanoma" ], "interventions": [ { "name": "TNO155", "type": "DRUG" }, { "name": "TNO155 in combination with EGF816 (nazartinib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 227, "start_date": "2017-05-26", "completion_date": "2025-07-04", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 4, "location_summary": "Tampa, Florida • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03114319" }, { "nct_id": "NCT06973564", "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "JAB-23E73", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jacobio Pharmaceuticals Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 294, "start_date": "2025-05-29", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-01-16", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 4, "location_summary": "Rochester, Minnesota • St Louis, Missouri • Cleveland, Ohio + 1 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06973564" }, { "nct_id": "NCT00955773", "title": "A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "GSK1120212 plus everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2009-08-17", "completion_date": "2011-11-08", "has_results": false, "last_update_posted_date": "2017-11-09", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 2, "location_summary": "Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00955773" }, { "nct_id": "NCT04965818", "title": "Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations", "Non-Small Cell Lung Cancer", "KRAS Gene Mutation" ], "interventions": [ { "name": "Futibatinib and Binimetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2021-09-20", "completion_date": "2023-09-21", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 3, "location_summary": "Santa Monica, California • Indianapolis, Indiana • Houston, Texas", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04965818" }, { "nct_id": "NCT07148128", "title": "Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced or Metastatic KRAS-mutant Tumor in Pancreatic Adenocarcinoma", "Advanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer", "Advanced or Metastatic KRAS-mutant Tumor in Non Small Cell Lung Cancer", "Advanced Solid Tumors", "Advanced or Metastatic KRAS-mutant Tumor" ], "interventions": [ { "name": "WEF-001", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Auricula Biosciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2025-07-28", "completion_date": "2028-01", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 2, "location_summary": "Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07148128" }, { "nct_id": "NCT03415126", "title": "A Study of ASN007 in Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Malignancy", "Neoplasia", "Neoplasm", "Neoplasm Metastasis", "Colon Cancer", "Colonic Neoplasms", "Colon Cancer Liver Metastasis", "Metastatic Cancer", "Metastatic Melanoma", "Metastatic Colon Cancer", "Metastatic Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Pancreatic Cancer", "Pancreas Cancer", "Pancreas Adenocarcinoma", "Pancreas Neoplasm", "Metastatic Nonsmall Cell Lung Cancer", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "ASN007: ascending doses", "type": "DRUG" }, { "name": "ASN007 RD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Asana BioSciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2018-01-19", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-07-09", "last_synced_at": "2026-06-25T18:03:49.105Z", "location_count": 5, "location_summary": "Tampa, Florida • Boston, Massachusetts • Houston, Texas + 1 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03415126" } ] }